HT-101 clinical trials
Also written HT-101.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses HT-101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HT-101
- 3
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Suzhou HepaThera Biotech Co., Ltd. (3)
Often tested with
Tested in the same studies.
HT-102 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test HT-101.
- Feb 2027A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus InfectionPhase 2 · Suzhou HepaThera Biotech Co., Ltd.
- Aug 2027A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus InfectionPhase 1/2 · Suzhou HepaThera Biotech Co., Ltd.
Studies
Open first, then newest update. How each study uses HT-101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- This is a Phase 1 Study in Which Healthy Volunteers and Participants With Chronic HBV Infection Will be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral ActivityCompletedPhase 1Suzhou HepaThera Biotech Co., Ltd.NCT06746311Written as HT-101
- A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus InfectionActive, not recruitingPhase 1/2Suzhou HepaThera Biotech Co., Ltd.NCT07183306Written as HT-101
- A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus InfectionActive, not recruitingPhase 2Suzhou HepaThera Biotech Co., Ltd.NCT07245953Written as HT-101